Literature DB >> 22259177

Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis.

J Verhulst1, L Ferdinande, P Demetter, W Ceelen.   

Abstract

BACKGROUND: Mucinous adenocarcinoma (MAC) of the colorectum has been known and studied for many years. The prognostic significance of this histological subtype remains controversial. The authors reviewed the prognostic significance of mucinous differentiation in colorectal cancer.
MATERIALS AND METHODS: A systematic web-based search was performed using Web of Knowledge and Medline. Articles published in English, German or French which used the WHO definition of MAC and described cohort studies, case-control studies or cross-sectional studies comparing survival in patients with MAC and adenocarcinoma (AC) not otherwise specified were included. Data on first author, year of publication, country, number of patients included, prevalence of MAC, % stage IV disease, % disease located in the proximal colon, mean age at presentation, % male patients and 5-year overall survival were extracted from individual studies. A fixed-effects meta-analysis model was used for analysis. The primary outcome was survival, expressed as the HR. Differences between categorical outcome parameters were quantified using the RR and corresponding 95% CI.
RESULTS: 44 studies and 222 256 patients were included. The RR for proximal disease versus distal disease was 1.55 (95% CI 1.53 to 1.58). Mucinous differentiation was less frequent in male subjects (RR 0.93 (95% CI 0.91 to 0.94)). Interestingly, the prevalence of stage IV disease was similar in MAC and AC (RR 0.99 (95% CI 0.96 to 1.02)). Thirty-five articles were included in the survival analysis. A worse survival in MAC versus AC was demonstrated (HR 1.05 (95% CI 1.02 to 1.08)). Conversely, three out of four studies reported a better survival in MAC with microsatellite instability (MSI). Due to heterogeneity a meta-analysis on the effect of MSI was not possible.
CONCLUSION: MAC more often originates from the right colon and is less frequent in male subjects. The authors did not identify a difference in the proportion of stage IV patients at presentation. Mucinous differentiation results in a 2-8% increased hazard of death, which persists after correction for stage. More research is needed to define the interaction between mucinous differentiation, MSI and outcome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22259177     DOI: 10.1136/jclinpath-2011-200340

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  75 in total

1.  Mapping clinicopathological entities within colorectal mucinous adenocarcinomas: a hierarchical clustering approach.

Authors:  Charly Liddell; Laure Droy-Dupré; Sylvie Métairie; Fabrice Airaud; Christelle Volteau; Stéphane Bezieau; Christian L Laboisse; Jean-François Mosnier
Journal:  Mod Pathol       Date:  2017-04-21       Impact factor: 7.842

2.  Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients.

Authors:  Vincenzo Catalano; Francesca Bergamo; Chiara Cremolini; Bruno Vincenzi; Francesca Negri; Paolo Giordani; Paolo Alessandroni; Rossana Intini; Silvia Stragliotto; Daniele Rossini; Beatrice Borelli; Daniele Santini; Donatella Sarti; Marco B L Rocchi; Sara Lonardi; Alfredo Falcone; Vittorina Zagonel; Rodolfo Mattioli; Francesco Graziano
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-06       Impact factor: 4.553

3.  Analysis of local recurrences after transanal endoscopic microsurgery for low risk rectal carcinoma.

Authors:  Theodor Junginger; Ursula Goenner; Mirjam Hitzler; Tong T Trinh; Achim Heintz; Wilfried Roth; Maria Blettner; Daniel Wollschlaeger
Journal:  Int J Colorectal Dis       Date:  2016-11-25       Impact factor: 2.571

Review 4.  Local excision for early rectal cancer: transanal endoscopic microsurgery and beyond.

Authors:  Azah A Althumairi; Susan L Gearhart
Journal:  J Gastrointest Oncol       Date:  2015-06

Review 5.  Mucinous carcinoma of the rectum: a distinct clinicopathological entity.

Authors:  M Chand; S Yu; R I Swift; G Brown
Journal:  Tech Coloproctol       Date:  2013-12-11       Impact factor: 3.781

6.  Prognosis of mucinous and signet-ring cell colorectal cancer in a population-based cohort.

Authors:  Ulrich Nitsche; Helmut Friess; Ayman Agha; Martin Angele; Renate Eckel; Wolf Heitland; Karl-Walter Jauch; Detlef Krenz; Natascha C Nüssler; Horst-Günter Rau; Reinhard Ruppert; Gabriele Schubert-Fritschle; Dirk Wilhelm; Jens Werner; Jutta Engel
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-29       Impact factor: 4.553

7.  The Impact of Histologic Subtype on Receipt of Adjuvant Chemotherapy and Overall Survival in Stage III Colon Cancer: a Retrospective Cohort Analysis.

Authors:  Benjamin D Powers; Seth I Felder; Iman Imanirad; Sophie Dessureault; Sean P Dineen
Journal:  J Gastrointest Cancer       Date:  2021-06

Review 8.  Advances in the care of patients with mucinous colorectal cancer.

Authors:  Niek Hugen; Gina Brown; Robert Glynne-Jones; Johannes H W de Wilt; Iris D Nagtegaal
Journal:  Nat Rev Clin Oncol       Date:  2015-09-01       Impact factor: 66.675

9.  Overall survival is improved in mucinous adenocarcinoma of the colon.

Authors:  J Hogan; J P Burke; G Samaha; E Condon; D Waldron; P Faul; J Calvin Coffey
Journal:  Int J Colorectal Dis       Date:  2014-01-15       Impact factor: 2.571

10.  Aberrant SOX2 expression in colorectal cancers does not correlate with mucinous differentiation and gastric mucin MUC5AC expression.

Authors:  Lalini Raghoebir; Katharina Biermann; Marjon Buscop-van Kempen; Hendrikus J Dubbink; Winand N M Dinjens; Remko Hersmus; Leendert H J Looijenga; Marco J Bruno; Dick Tibboel; Robbert J Rottier; Ron Smits
Journal:  Virchows Arch       Date:  2014-08-10       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.